.jpg)
Aravax Continues International Expansion with Appointment of Aled Williams as Chief Business Officer
Melbourne, Australia and Oxford, UK– 21 January 2025 , Aravax, a clinical-stage biotechnology company developing precisely targeted...
Jan 20
Aravax Establishes Pharmaceutical Development base on the Oxford Science Park with a Focus on Developing Manufacturing Capabilities in the UK
Melbourne, Australia and Oxford, UK– 14 November 2024, Aravax, a clinical-stage biotechnology company developing next-generation...
Nov 13, 2024
Aravax Completes Recruitment into Phase 2 Study of PVX108, a novel immunotherapy for the Treatment of Peanut Allergy
Melbourne, Australia – 28 October 2024: Aravax, a clinical-stage biotechnology company developing next-generation immunotherapies...
Oct 28, 2024
Aravax Appoints Dr Paul Laidler as VP Pharmaceutical Development
1 May 2024, Melbourne, Australia: Aravax, a clinical-stage biotechnology company developing next- generation immunotherapies which are...
Apr 30, 2024
Aravax closes Series B round with US$42m to accelerate Phase 2 development for peanut allergy therapy
23 Jan 2024: Aravax, a clinical stage biotechnology company developing the first rationally designed and precisely targeted...
Jan 23, 2024
Aravax appoints Annette Leahy as Director of Clinical Operations
21 July 2023, Melbourne, Australia: Aravax, a clinical-stage biotechnology company developing next- generation immunotherapies which are...
Jul 21, 2023